Sympathetic activation secondary to chronic kidney disease: Therapeutic target for renal denervation?

Esther De Beus, Rosa De Jager, Jaap A. Joles, Guido Grassi, Peter J. Blankestijn

Research output: Contribution to journalArticlepeer-review


Percutaneous ablation of the renal nerves [renal denervation (RDN)] has recently become available for treatment of (therapy-resistant) hypertension. In this review, the potential importance of RDN for patients with chronic kidney disease (CKD) is discussed. An overview of the role of the renal nerves is given, and the role of the kidneys as both generators and recipients of sympathetic hyperactivity is described. The clinical relevance of increased sympathetic nervous system activity in CKD is reviewed, and the effects of conventional treatment on sympathetic hyperactivity are summarized. Next, we present the current knowledge on the effect of RDN in CKD from both experimental and clinical studies. Finally, we discuss how this knowledge may help us in predicting the effect of RDN in hypertensive patients and ways to monitor the effect of the procedure itself.

Original languageEnglish
Pages (from-to)1751-1761
Number of pages11
JournalJournal of Hypertension
Issue number9
Publication statusPublished - 2014


  • chronic kidney disease
  • renal denervation
  • sympathetic activity

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)


Dive into the research topics of 'Sympathetic activation secondary to chronic kidney disease: Therapeutic target for renal denervation?'. Together they form a unique fingerprint.

Cite this